Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Checkpoint-blockade immunotherapy has transformed cancer therapeutics but still benefits only a subset of patients. The development of more-robust biomarkers of response could change that.
Gender-affirming care for transgender and gender diverse people should be inclusive, community led and evidence informed to support mental health and wellbeing.
Nature Medicine explores the latest translational and clinical research news, with an immunotherapy that delays the onset of type 1 diabetes in high-risk children and adults.
An mRNA-based vaccine encoding antigens from all known influenza virus A and B subtypes worked well in animal models — which offers hope for broad protection in humans.
To prevent irreversible organ damage, an infant with early-onset Pompe’s disease was treated in utero; early data suggest improved outcomes and safety of this approach.
Nature Medicine explores the latest translational and clinical research news, with news that sotatercept met its primary endpoint in the STELLAR trial.
In a first in-human study, researchers used an array of technologies to generate highly personalized cell therapy products for patients with solid tumors.
Changing gloves and instruments before wound closure significantly reduces the infection rate, offering a low-cost and impactful way to mitigate this global problem.
99% of clinical trials for Alzheimer’s disease fail to show positive results, but researchers remain optimistic that new disease-modifying treatments are on the horizon
New initiatives aimed at reducing the burden of diabetes are laudable, but they will have to account for the disease’s complexity and heterogeneity to be truly effective and equitable at a global scale.
The initiation of gender-affirming treatment before puberty is controversial; a Dutch study finds that the vast majority of adolescents who initiated this treatment continued it into adulthood, which may alleviate some concerns.
An immense genetic analysis identifies the majority of common height-associated variants, providing proof of principle that the genetics of other complex traits and diseases could be determined.